Hematology

Filter

Gene therapy

EBMT 2026: Gene Therapy Adoption Gaps in Sickle Cell Care

March 2026

Survey data reveal strong support for gene therapy in sickle cell disease, but inconsistent referral practices, limited knowledge, and insurance barriers hinder implementation.

Gene therapy

EBMT 2026: Gene Therapy Adoption Gaps in Sickle Cell Care

Survey data reveal strong support for gene therapy in sickle cell disease, but inconsistent referral practices, limited knowledge, and insurance barriers hinder implementation.

Konstanze Döhner, President Elect, European Hematology Association (EHA); Department of Internal Medicine III, University Hospital of Ulm, Germany.

EHA Interview 2025: Konstanze Döhner

EMJ spoke with Konstanze Döhner, President Elect of the European Hematology Association, about her priorities for the future of haematology, challenges in research and patient care, and the vision behind the EHA2025 theme “Borderless Hematology”.

Martin Dreyling, Professor of Medicine and Head of the Lymphoma Programme, Ludwig Maximilian University, Germany; Scientific Program Committee Chair EHA2025 European Hematology Association (EHA)

EHA Interview 2025: Martin Dreyling

EMJ spoke with Martin Dreyling, Chair of the EHA2025 Scientific Program Committee, about his career journey, what attendees can expect from the upcoming congress, and the vision behind its programme.

Review of the European Hematology Association (EHA) 2025 Congress

THE 30ᵗʰ EUROPEAN Hematology Association (EHA) Congress was held in the beautiful city of Milan, Italy from the 12ᵗʰ–15ᵗʰ of June 2025…

Prognostic Assessment in AL Amyloidosis

Systemic light chain (AL) amyloidosis is a rare plasma cell dyscrasia characterised by the extracellular deposition of misfolded Ig light…

Putting Patients First in Haematology

During the Specialized Working Group session, ‘Quality of Life and Symptoms: Promoting Connection Between Patients and Clinicians’, which…

EHA 2025 Highlights in Acute Lymphoblastic Leukemia

The most important advances in Ph-negative ALL come from the incorporation of immunotherapy into first-line ALL. In this sense…

Advancing Frontiers in Myeloproliferative Neoplasms

THE 30th EUROPEAN Hematology Association (EHA) Congress marked a pivotal year in advancing the treatment and understanding…

Loading posts...